Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells. [electronic resource]
Producer: 20201020Description: 8010-8018 p. digitalISSN:- 1582-4934
- Antineoplastic Agents -- pharmacology
- Bone Marrow -- drug effects
- Bortezomib -- pharmacology
- Carcinogenesis -- drug effects
- Cell Line, Tumor
- Cell Survival -- drug effects
- Chemokine CXCL10 -- metabolism
- Humans
- Interleukin-6 -- metabolism
- Interleukin-8 -- metabolism
- Multiple Myeloma -- drug therapy
- Oligopeptides -- pharmacology
- Proteasome Endopeptidase Complex -- genetics
- Proteasome Inhibitors -- pharmacology
- Proteomics
- Recurrence
- STAT3 Transcription Factor -- antagonists & inhibitors
- STAT6 Transcription Factor -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Tumor Microenvironment -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.